DK3006462T3 - Alfa-1-antitrypsin-sammensætning - Google Patents

Alfa-1-antitrypsin-sammensætning Download PDF

Info

Publication number
DK3006462T3
DK3006462T3 DK15193455.1T DK15193455T DK3006462T3 DK 3006462 T3 DK3006462 T3 DK 3006462T3 DK 15193455 T DK15193455 T DK 15193455T DK 3006462 T3 DK3006462 T3 DK 3006462T3
Authority
DK
Denmark
Prior art keywords
alpha
antitrypsin
composition
antitrypsin composition
Prior art date
Application number
DK15193455.1T
Other languages
English (en)
Inventor
Scott M Kee
Paul I Cook
James R Smith
Robert Kling
Scott A Fowler
David Weber
Original Assignee
Csl Behring Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32655016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3006462(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Behring Llc filed Critical Csl Behring Llc
Application granted granted Critical
Publication of DK3006462T3 publication Critical patent/DK3006462T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/38—Flow patterns
    • G01N30/46—Flow patterns using more than one column
    • G01N30/461—Flow patterns using more than one column with serial coupling of separation columns

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DK15193455.1T 2002-12-31 2003-12-19 Alfa-1-antitrypsin-sammensætning DK3006462T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/334,303 US7777006B2 (en) 2002-12-31 2002-12-31 Method for purification of alpha-1-antitrypsin
EP10182334.2A EP2295126B1 (en) 2002-12-31 2003-12-19 Alpha-1-antitrypsin composition

Publications (1)

Publication Number Publication Date
DK3006462T3 true DK3006462T3 (da) 2019-06-17

Family

ID=32655016

Family Applications (3)

Application Number Title Priority Date Filing Date
DK03814875.5T DK1590061T3 (da) 2002-12-31 2003-12-19 Fremgangsmåde til rensning af alfa-1-antitrypsin
DK10182334.2T DK2295126T3 (da) 2002-12-31 2003-12-19 Alpha-1-antitrypson-sammensætning
DK15193455.1T DK3006462T3 (da) 2002-12-31 2003-12-19 Alfa-1-antitrypsin-sammensætning

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK03814875.5T DK1590061T3 (da) 2002-12-31 2003-12-19 Fremgangsmåde til rensning af alfa-1-antitrypsin
DK10182334.2T DK2295126T3 (da) 2002-12-31 2003-12-19 Alpha-1-antitrypson-sammensætning

Country Status (12)

Country Link
US (8) US7777006B2 (da)
EP (4) EP3006462B1 (da)
JP (1) JP5249489B2 (da)
AU (2) AU2003301108B2 (da)
CA (1) CA2511986C (da)
DK (3) DK1590061T3 (da)
ES (3) ES2564627T3 (da)
HU (2) HUE027327T2 (da)
LU (1) LU93072I2 (da)
PT (1) PT1590061E (da)
SI (2) SI2295126T1 (da)
WO (1) WO2004060528A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
CA2534352A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
ATE391730T1 (de) * 2003-09-22 2008-04-15 Kamada Ltd Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
JP2007534633A (ja) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
GB2446550B (en) * 2005-11-28 2010-12-08 Proteomtech Inc Methods for production of recombinant alpha1-antitrypsin
GB0524432D0 (en) * 2005-11-30 2006-01-11 Nhs Blood & Transplant Method
WO2007134800A1 (en) * 2006-05-19 2007-11-29 Baxter International Inc. Ethanol dependence of alpha1 antitrypsin c-terminal lys truncation by basic carboxypeptidases
WO2009025754A2 (en) 2007-08-17 2009-02-26 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
AU2009270723A1 (en) * 2008-07-18 2010-01-21 Grifols Therapeutics Inc. Method of preparing alpha-1 proteinase inhibitor
PT2496246T (pt) * 2009-11-03 2018-07-31 Grifols Therapeutics Llc Composição, método e kit para o inibidor da alfa-1 protease
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
SG10201508401TA (en) * 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
CN102558295A (zh) * 2010-12-28 2012-07-11 同路生物制药有限公司 生产α1抗胰蛋白酶的方法
CN102180966B (zh) * 2011-01-28 2013-04-03 哈尔滨派斯菲科生物制药股份有限公司 一种规模化生产人α1-抗胰蛋白酶的方法
US9353165B2 (en) 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
DK3004160T3 (da) * 2013-06-05 2023-01-23 Csl Ltd Fremgangsmåde til fremstilling af apolipoprotein a-i (apo a-i)
WO2015070075A1 (en) * 2013-11-07 2015-05-14 Medical Discovery Partners Llc Quantitative controls and calibrators for cellular analytes
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107163138B (zh) * 2017-03-28 2021-02-09 深圳市卫光生物制品股份有限公司 一种人血浆蛋白α1-抗胰蛋白酶的分离纯化方法
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
WO2021054999A1 (en) * 2019-09-20 2021-03-25 Plasma Technologies, Llc Therapeutic protein compositions and methods
CN112409476B (zh) * 2020-08-13 2022-03-29 中元汇吉生物技术股份有限公司 四种血液来源蛋白的纯化方法
WO2026008645A1 (en) * 2024-07-02 2026-01-08 Institut National de la Santé et de la Recherche Médicale Aerosolization of apolipoprotein a1 nanoparticles enriched with alpha-1-antitrypsin for the treatment of pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL289662A (da) 1962-03-03
DE1189674B (de) 1963-06-12 1965-03-25 Behringwerke Ag Verfahren zur Isolierung von alpha-Antitrypsin
US3293326A (en) 1965-07-06 1966-12-20 Sun Oil Co Dyeable interpolymers consisting of alpha-olefins and a nitrogen containing compound
US4440679A (en) 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4623717A (en) 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
DE3271827D1 (en) 1981-05-01 1986-07-31 Medical Research Inst Of San F Method for isolating alpha-1-antitrypsin
JPS584728A (ja) * 1981-05-01 1983-01-11 メデイカル・リサ−チ・インステイチユ−ト・オブ・サンフランシスコ・コ−ポレ−シヨン α−１−抗トリプシンの精製
US4379087A (en) 1982-06-17 1983-04-05 Cutter Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4439358A (en) 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
JPS59128335A (ja) 1983-01-12 1984-07-24 Fujirebio Inc α↓１−アンチトリプシンの分離取得方法
US4820805A (en) 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
US4683294A (en) 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4684723A (en) 1985-09-11 1987-08-04 Miles Laboratories, Inc. Method of separating proteins from aqueous solutions
US4697003A (en) 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4656254A (en) 1985-12-02 1987-04-07 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor and antithrombin III
US4629567A (en) * 1986-03-07 1986-12-16 Smithkline-Rit Alpha-1-antiprotease purification
DE3615171A1 (de) 1986-05-05 1987-11-12 Hans Ing Grad Kern Einrichtung zum reinigen von rohrleitungen
US4749783A (en) 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
US5114863A (en) 1986-09-30 1992-05-19 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody
FR2610633B1 (fr) 1987-02-05 1992-09-18 Lille Transfusion Sanguine Procede d'obtention d'un concentre d'a 1-antitrypsine a partir de plasma humain et son utilisation a titre de medicament
DE3877041T2 (de) * 1987-04-27 1993-04-22 Miles Inc Verfahren zur herstellung von hochgereinigtem alpha-1-proteinase-inhibitor.
US4876241A (en) 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
MY105067A (en) 1988-10-13 1994-07-30 Novartis Ag Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof.
US5169936A (en) 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
ATE113441T1 (de) 1989-10-02 1994-11-15 Sandoz Nutrition Ltd Proteinhydrolysaten.
US6187572B1 (en) 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
FR2672895B1 (fr) 1991-02-15 1995-05-12 Transgene Sa Procede de purification d'une proteine fortement glycosylee.
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
WO1993017724A1 (en) 1992-03-02 1993-09-16 Bioeng, Inc. Viral inactivation method
IT1271463B (it) * 1993-12-16 1997-05-28 Sclavo Spa Processo per l'estrazione e purificazione dell'alfal-antitripsina (alfal-pi)dalla frazione iv-1 di cohn.
DE4407837C1 (de) 1994-03-09 1995-08-17 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem alpha¶1¶-Antitrypsin mittels Anionenaustauscher-Chromatographie
US6096216A (en) 1994-06-09 2000-08-01 American National Red Cross Iodinated matrices for disinfecting biological fluids
US6284874B1 (en) 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
AT407114B (de) * 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
US6093804A (en) 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6106773A (en) 1998-09-24 2000-08-22 American National Red Cross Pathogen inactivating compositions for disinfecting biological fluids
US6403646B1 (en) * 1999-06-30 2002-06-11 David H. Perlmutter Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies
US6436344B1 (en) 1999-11-02 2002-08-20 American National Red Cross Method of inactivating pathogens
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
CA2427643C (en) 2000-11-02 2014-04-15 Molecular Discoveries, L.L.C. Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
NZ526940A (en) 2000-12-14 2005-06-24 Bayer Healthcare Llc Method of preparing alpha-1 proteinase inhibitor
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
US10334303B1 (en) 2014-12-31 2019-06-25 The Directv Group, Inc. Systems and methods for personalized feature setup and parental guidance sensing

Also Published As

Publication number Publication date
US20200078451A1 (en) 2020-03-12
US10335467B2 (en) 2019-07-02
HUS1600026I1 (hu) 2016-06-28
WO2004060528A1 (en) 2004-07-22
US20150320846A1 (en) 2015-11-12
US20120165261A1 (en) 2012-06-28
ES2515816T3 (es) 2014-10-30
ES2733841T3 (es) 2019-12-03
AU2009248429B2 (en) 2012-02-23
US8124736B2 (en) 2012-02-28
EP1590061A4 (en) 2006-08-09
HK1152007A1 (en) 2012-02-17
EP3543254A1 (en) 2019-09-25
SI2295126T1 (sl) 2016-05-31
PT1590061E (pt) 2014-10-23
SI1590061T1 (sl) 2015-06-30
US20180200347A1 (en) 2018-07-19
US9320783B2 (en) 2016-04-26
EP2295126B1 (en) 2015-12-16
US20040124143A1 (en) 2004-07-01
EP1590061A1 (en) 2005-11-02
US20140323405A1 (en) 2014-10-30
AU2009248429A1 (en) 2010-01-07
US20100310550A1 (en) 2010-12-09
US7777006B2 (en) 2010-08-17
DK1590061T3 (da) 2014-10-13
AU2003301108A1 (en) 2004-07-29
AU2003301108B2 (en) 2009-09-10
CA2511986A1 (en) 2004-07-22
HUE027327T2 (en) 2016-10-28
EP2295126A1 (en) 2011-03-16
ES2564627T3 (es) 2016-03-28
DK2295126T3 (da) 2016-02-29
US9950046B2 (en) 2018-04-24
EP1590061B1 (en) 2014-08-06
CA2511986C (en) 2012-02-28
JP5249489B2 (ja) 2013-07-31
US20170042986A1 (en) 2017-02-16
US8722624B2 (en) 2014-05-13
LU93072I2 (fr) 2016-07-12
EP3006462B1 (en) 2019-04-10
US11224643B2 (en) 2022-01-18
JP2006512394A (ja) 2006-04-13
EP3006462A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
DE10393374D2 (de) Zusammensetzung
FR2862654B1 (fr) Composition amylacee filmogene
DK3473251T3 (da) Nikotin-cellulose-kombination
DE60328309D1 (de) Ssigkeiten
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
ATE427876T1 (de) Luftkissenboot
ATE318817T1 (de) Aza-arylpiperazine
DE50212349D1 (de) Hirurgie
EP1559433A4 (en) STABILIZED COMPOSITION
DK1561472T3 (da) Faststofsammensætning
ATE349458T1 (de) Etonogestrelester
DE60320902D1 (de) Zusammensetzungen mit ausgelöster Freisetzung
SE0500163L (sv) Sammansättning
ATA1572002A (de) Managementspleisskassette
ATA4142004A (de) Trägerverbau
EP1561467A4 (en) COMPOSITION FOR RECOVERING DAMAGED SKIN
ATE469773T1 (de) Zugöse
FI20030333A0 (fi) MSM-anturi
DE50209283D1 (de) Tropfbewässerungsrohr
ATA19152002A (de) Hubkupplung
NO20044140D0 (no) New Composition
ATE396192T1 (de) N-sulfonylaminothiazole
DE10244834B8 (de) Suszeptometer
DE10211707A8 (de) Segmentstatormaschine